Shares of Zydus Lifesciences Ltd are trading flat after hitting a day’s high of Rs 958 on 19th June. This comes after the company announced on Wednesday that a recent inspection by the US FDA at its oncology injectable facility in Ahmedabad concluded with two observations — none related to data integrity.

Zydus Lifesciences has announced that the US FDA has completed a follow-up GMP inspection at its oncology injectable plant in Ahmedabad, conducted between 9th and 18th June 2025. 

The inspection concluded with two minor observations that are unrelated to data integrity. The company said it will work closely with the FDA to address them quickly.

This update comes after Zydus recently received an Establishment Inspection Report (EIR) for its API manufacturing facility in Ankleshwar, Gujarat. 

That inspection carried out from 10th to 14th March 2025 was classified as ‘No Action Indicated’ (NAI), meaning the FDA found no issues and closed the inspection.

At 11:12 AM, the shares of Zydus Lifesciences were trading 0.45% lower at Rs 953.95 on NSE.

Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!